NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIA E-049-2001-0-AU-24 GLP-1 Exendin-4 Peptide Analogs and Uses Thereof AU DIV 2014277804 Expired
NCATS E-326-2008-0-US-10 Activators Of Human Pyruvate Kinase US DIV 14/576,333 9290512 Issued PDF
NCI E-549-2013-0-PCT-02 IMMUNOGENIC JC POLYOMAVIRUS COMPOSITIONS AND METHODS OF USE PCT PCT PCT/US2014/071621 Expired
NEI E-089-2011-0-PCT-02 Calcineurin Inhibitor-antibody Conjugates For The Treatment Of Th17 Driven Inflammatory Diseases. PCT PCT PCT/GB2014/053804 Expired
NINDS E-088-2012-0-US-03 METHODS AND COMPOSITIONS FOR IDENTIFYING JC VIRUS US National Stage 14/408,919 9631243 Issued PDF
NCI E-050-2014-0-CA-04 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CA National Stage 2934075 Issued
NCI E-050-2014-0-MX-13 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon MX National Stage MX/a/2016/007726 Issued
NCI E-050-2014-0-NL-30 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON NL EP 20150087.3 Issued
NCI E-050-2014-0-BE-22 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON BE EP 20150087.3 Issued
NCI E-050-2014-0-CH-23 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON CH EP 20150087.3 Issued
NCI E-050-2014-0-ES-25 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON ES EP 20150087.3 Issued
NCI E-050-2014-0-IE-28 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON IE EP 20150087.3 Issued
NCI E-050-2014-0-DE-24 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON DE EP 20150087.3 Issued
NCI E-050-2014-0-IT-29 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON IT EP 20150087.3 Issued
NCI E-050-2014-0-FR-26 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON FR EP 20150087.3 Issued
NCI E-050-2014-0-GB-27 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON GB EP 20150087.3 Issued
NCI E-050-2014-0-IN-11 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP REPLICON IN National Stage 201617023312 Issued
NCI E-050-2014-0-JP-06 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon JP National Stage 2016-558546 Issued
NCI E-050-2014-0-AU-03 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon AU National Stage 2014365777 Issued
NCI E-050-2014-0-SG-14 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon SG National Stage 11201604868Y Issued
NCI E-203-2004-0-US-03 Improved Replication-Competent Adenoviral Vectors US DIV 14/571,942 9216214 Expired PDF
NCI E-050-2014-0-PCT-02 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon PCT PCT PCT/US2014/070552 Expired
NCI E-050-2014-0-CN-09 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CN National Stage 201480074163.2 Abandoned
NCI E-050-2014-0-BR-08 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon BR National Stage BR112016013804-0 Abandoned
NCI E-050-2014-0-EP-05 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon EP National Stage 14824680.4 Abandoned
NIAID E-048-2015-0-US-01 Detection And Discrimination Of Classical And Atypical L-Type BSE Strains By RT-QuIC US 62/092,645 Abandoned
NCI E-108-2004-2-US-02 Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas US CON 14/570,316 1037-07-15 Expired PDF
NIA E-045-2012-0-US-02 THIO COMPOUNDS US DIV 14/571,138 9084783 Issued PDF
NCI E-047-2014-0-CA-03 Multi-Epitope TARP Peptide Vaccine And Uses Thereof CA National Stage 2932248 Issued
NICHD E-348-2013-0-US-05 Biomarker Test for Prediction or Early Detection of Preeclampsia and/or HELLP Syndrome US National Stage 14/407,516 1067-06-10 Issued PDF
NCI E-047-2014-0-AU-07 Multi-Epitope TARP Peptide Vaccine And Uses Thereof AU National Stage 2014361788 Issued
NCI E-047-2014-0-GB-10 Multi-Epitope TARP Peptide Vaccine And Uses Thereof GB EP 14831120.2 Issued
NCI E-047-2014-0-CH-11 Multi-Epitope TARP Peptide Vaccine And Uses Thereof CH EP 14831120.2 Issued
NCI E-047-2014-0-NL-13 Multi-Epitope TARP Peptide Vaccine And Uses Thereof NL EP 14831120.2 Issued
NCI E-047-2014-0-FR-09 Multi-Epitope TARP Peptide Vaccine And Uses Thereof FR EP 14831120.2 Issued
NCI E-047-2014-0-DK-12 Multi-Epitope TARP Peptide Vaccine And Uses Thereof DK EP 14831120.2 Issued
NCI E-047-2014-0-DE-08 Multi-Epitope TARP Peptide Vaccine And Uses Thereof DE EP 14831120.2 Issued
NCI E-047-2014-0-EP-04 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP National Stage 14831120.2 Issued
NCI E-081-2015-1-AU-02 HUMAN BISPECIFIC EGFRVIII ANTIBODY ENGAGING MOLECULES AU National Stage 2013271428 Abandoned
NCI E-047-2014-0-PCT-02 Multi-Epitope TARP Peptide Vaccine And Uses Thereof PCT PCT PCT/US2014/070144 Expired
NICHD E-348-2013-0-IL-04 BIOMARKER TEST FOR PREDICTION OR EARLY DETECTION OF PREECLAMPSIA AND/OR HELLP SYNDROME IL National Stage 236180 Issued
NCI E-077-2017-0-US-03 CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE US National Stage 14/407,419 10286064 Issued PDF
NIA E-051-2008-0-JP-10 Compositions and Methods for Delivering Inhibitory Oligonucleotides JP DIV 2014-250963 Abandoned
NCI E-248-2016-0-US-01 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer US 62/089,631 Abandoned
NCATS E-203-2012-0-US-07 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 US National Stage 14/406,401 9730941 Issued PDF
NCI E-081-2015-1-JP-05 HUMAN BISPECIFIC EGFRVIII ANTIBODY ENGAGING MOLECULES JP National Stage 2015-516235 Issued
NICHD E-032-2008-0-US-05 Use Of Saccharides Cross-reactive With Bacillus Anthracis Spore Glycoprotein As A Vaccine Against Anthrax. US DIV 14/563,920 Abandoned
NCI E-021-2015-0-US-01 Anti-CD70 Chimeric Antigen Receptors US 62/088,882 Abandoned
NCATS E-203-2012-0-JP-06 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 JP National Stage 2015-516246 Abandoned
NCI E-269-2011-0-JP-05 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) JP National Stage 2015-516223 Issued